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Targeting Specific PDZ Domains of PSD-95:
Structural Basis for Enhanced Affinity
and Enzymatic Stability of a Cyclic Peptide
COOH consensus motif (where X stands for any amino
acid). The binding cleft or pocket of the PDZ domain is
shallow and nondescript, consistent with the short-
lived, transient interactions aimed to bring proteins to-
gether to facilitate signaling and then rapidly disperse.
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Although sequentially and structurally similar, the PDZDivision of Biology & Medicine
domains of PSD-95 in fact exhibit distinct preferencesBrown University
for binding partners. Unfortunately, the origin of the PDZProvidence, Rhode Island 02912
domain specificity is still not well understood. Binding3 Department of Chemistry
studies based on peptide libraries have shown that allWayne State University
of the last five C-terminal residues actively contributeDetroit, Michigan 48202
to the interaction. Indeed, the X-ray analysis of the com-
plex of PDZ3 with the C terminus of CRIPT provides
structural information for only the last five residues ofSummary
CRIPT [4]. NMR studies of PDZ1 and PDZ2 of PSD-95
[5, 6] have shown that the loop between the secondA cyclic peptide, Tyr-Lys-c[-Lys-Thr-Glu(Ala)-]-Val,
and third  strands is affected by ligand association,incorporating a -Ala lactam side chain linker and de-
suggesting that the loop plays an important role in thesigned to target the PDZ domains of the postsynaptic
binding process and maybe in ligand specificity.density protein 95 (PSD-95), has been synthesized
As a first step to increase both the binding and speci-and structurally characterized by NMR while free and
ficity of the peptide ligands for the PDZ domains of thebound to the PDZ1 domain of PSD-95. While bound,
PSD-95, we have designed, synthesized, and examinedthe lactam linker of the peptide makes a number of
the structural features of a novel cyclic analog whileunique contacts outside the canonical PDZ binding
bound to the PDZ1 domain of PSD-95. The resultingmotif, providing a novel target for PDZ-domain speci-
structural features indicate that the side chain to sideficity as well as producing a 10-fold enhancement in
chain lactam bridge stabilizes the extended structurebinding affinity. Additionally, the cyclization greatly en-
required for binding, leading to a 10-fold enhancement
hances the enzymatic stability, increasing the duration
in binding and affords a mechanism for enhanced PDZ
that the peptide inhibits the association between specificity. Additionally, the cyclic peptide displays a
PSD-95 and glutamate receptors, effectively inhibiting longer duration of biological function, a fact of dimin-
the clustering of kainate receptors for over 14 hr after ished enzymatic degradation.
application. Highly specific regulation of kainate re-
ceptor action may provide a novel route for treatment Results and Discussion
of drug addiction and epilepsy.
Peptide Design
Introduction As part of a program to develop novel ligands for the
PDZ domain, a bridged cyclic peptide scaffold was de-
The postsynaptic density protein 95 (PSD-95), also signed that allows for systematic variation in ring size
known as synapse associated protein-90 (SAP-90), reg- [7]. The cyclic peptide was designed based on the six
ulates signaling in glutaminergic neurons by acting as C-terminal residues of CRIPT, where Ser1 and Gln3
a molecular scaffold for the formation of protein com- (starting from the C terminus, Val is indicated as position
plexes localized at the postsynaptic density of dendritic 0) have been replaced by glutamic acid and lysine, re-
spines. Each of the five domains of PSD-95 [1-3]—three spectively. These two side chains were then cyclized
PDZ, an SH3, and an inactive guanylate kinase domain— using -alanine as a linker (Figure 1). We previously have
can individually (or in tandem) interact with several tar- shown that the C-terminal peptide of CRIPT binds to
gets, including ion channel receptors, adhesion and PDZ1 of PSD-95 with a dissociation constant of 10 M
cytoskeleton proteins, and proteins involved in intracel- [5]. The cyclization was designed to stabilize an ex-
lular signaling. In particular, the three PDZ domains are tended conformation of the peptide as observed for
important in the modulation of these protein-protein in- PDZ3 bound form of CRIPT. Indeed, the NMR-derived
teractions. structures of the free cyclic peptide revealed limited
The PDZ domains of PSD-95 share high sequence conformations (in comparison to linear peptides) with
homology and have similar three-dimensional structures similar features to the structure while bound to PDZ1.
[4-6] resembling the canonical PDZ conformation con- Based on the high-resolution structure of the peptide
alone in aqueous solution (data not shown), the averagesisting of an antiparallel  sandwich formed by two 
distance between the C of K3 and Val0 is 9.2 A˚, onlyhelices and six  strands. The binding pocket, located
0.4 A˚ shorter than while associated with PDZ1.between the second  strand and the first  helix, binds
the C termini of proteins sharing the (S/T)-X-(V/I/L)-
Structure of the Peptide/PDZ1 Complex
In the presence of PDZ1, the resonances of the peptide*Correspondence: dale_mierke@brown.edu; mspaller@chem.wayne.
edu undergo frequency shifts and line broadening, indicating
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Outside the ligand binding pocket, the perturbation
of NMR signals is generally diminished, with the excep-
tion of residues of the 2-3 loop. The involvement of
this loop in the ligand recognition process represents
an important differentiation of ligand binding to PDZ1
and PDZ3 of PSD-95. In the PDZ3/CRIPT X-ray struc-
ture, the residues preceding Lys4 do not diffract; they
are unstructured and do not contribute to the binding
[4]. One can conclude the short 2-3 loop of PDZ3
(approximately six residues) precludes significant inter-Figure 1. Design of Cyclic Ligand
action between the loop and C terminus of CRIPT. An
Structural formula of the cyclic lactam containing peptide, Tyr-Lys-
active role of the 2-3 loop in ligand recognition hasc[-Lys-Thr-Glu(Ala)-]-Val, examined here.
been reported for the PDZ2 domain from human tyro-
sine-phosphatase hPTP1E [8]. In the structure of PDZ2
of hPTP1E, an Asn residue in the middle of the 2-3a fast exchange regime between the bound and un-
loop is proposed to hydrogen bond with the ligand,bound forms. From a careful titration of PDZ1 with the
interacting with a Glu carboxylic acid in position 5 ofpeptide, a dissociation constant of 1 M is calculated
the peptide. Here, a number of intermolecular NOEs arefor the cyclic peptide (Figure 2). Based on numerous
detected for Tyr-5 placing the side chain in a gap formedNOEs (Table 1), the peptide binds to PDZ1 in the groove
by the end of the 2 strand and the large 2-3 loop.between the 2 strand and 2 helix as previously re-
Although few intermolecular NOEs are observed for theported for other peptides [5] (Figure 3). The peptide
Lys4 side chain, the backbone carbonyl forms hydro-backbone encompassing residues Val0 and Thr2 forms
gen bonds to the side chain amide of Asn85. In our previ-an additional antiparallel  strand interacting with Phe77,
ous study of the C terminus of the GluR6 subunit ofSer78, and Ile79 of the 2 strand of PDZ1 (Figure 4). The
kainate receptors [5], a similar perturbation of the Asn85chemical shift perturbations of the backbone reso-
side chain was observed, consistent with an interactionnances of PDZ1 upon ligand titration are consistent with
originated by the ligand backbone.the NOE-derived structure: the 1H15N amide resonances
The lactam ring including Glu1, Lys3, and the -Alashift toward lower field, indicating an increase in hydro-
linker not only preserves the canonical binding of PDZgen bond content, while the 13C1H chemical shifts move
ligands, but by extending over the surface of the  sheet,toward more accentuated  sheet values.
actively contributes to the binding affinity. The sideThe side chain of Val0 is in a hydrophobic binding
chains of both Glu1 and Lys3 are involved in a numberpocket formed by Leu75, Phe77, Ile78, and Leu137. The
of NOEs with residues of the 2 and 3 strands, namelyC-terminal carboxylic acid is surrounded by the amide
Ser78, Ala80, Lys98, and Ile100. The lactam containing ringgroups of Leu75, Gly76, and Phe77, whose NMR reso-
adopts a square-like conformation, with the fully ex-nances are strongly shifted toward lower field, consis-
tended side chains of Glu1 and Lys3 projecting perpen-tent with formation of hydrogen bonds. The hydroxyl
dicularly to the 2-strand and the -Ala linker, connect-group of Thr2 hydrogen bonds the imidazole moiety
ing Glu1 and Lys3 and running antiparallel atop the 3of His130, while the methyl group makes hydrophobic
strand of PDZ1. Given the sequence variation of thiscontacts with Ile79 on the 2 strand and with Val134 on
the helix side. region within different PDZ domains, ligand/receptor
Figure 2. NMR-Based Ligand Binding
1H,15N HSQC NMR spectrum of the PDZ1 do-
main of PSD-95 during the titration of the li-
gand. Some of the amide resonances de-
scribed in the text are denoted.
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Figure 3. Ligand/PDZ1 Complex
Structure of the peptide/PDZ1 complex as
determined by NMR. Left, a superposition
(using the heavy backbone atoms of the PDZ1
domain) of 23 structures from the structure
refinement calculations. Right, a ribbon rep-
resentation of one structure, illustrating the
mode of ligand binding and the lactam linker,
extending over the 2 strand defining the ca-
nonical binding pocket.
interactions here may be targeted for enhanced PDZ development of analogs with the desirable properties
specificity. of high affinity and PDZ domain specificity. The novel
macrocyclic cyclic peptide described here presents a
Biological Function Assays method to address both of these issues. The cyclic pep-
We have previously shown that the association of the tide displays a 10-fold increase in binding affinity. As
GluR6 subunit of the kainite receptor and PSD-95 is the NMR-based structural studies indicate, the lactam
mediated through the C terminus of GluR6 and PDZ1
of PSD-95 [9]. To examine the activity of the cyclic pep-
tide, the GluR6 and PSD-95 cDNAs are transfected into
HEK293 cells, and after 24 hr, peptides are transduced
into the cells using the bioporter reagent. In this assay,
a 5- to 10-fold smaller quantity of the cyclic peptide was
required to disrupt the interaction of GluR6 and PSD-95
verses a control peptide (containing the final 15 amino
acids of the C terminus of GluR6). As illustrated in Figure
5, the cyclic peptide, at a concentration of 8 g/ml, is
very efficient in competing against the C terminus of
GluR6 for the PDZ1 domain, whereas 40g/ml of control
peptide was necessary to produce a similar disruption.
The cyclic peptide also displays a more rapid onset of
activity and, presumably because of reduced peptide
enzymatic degradation, a much longer duration of bio-
logical function.
A similar response is observed in a cell-based assay.
Previously, we found that PSD-95 promoted cluster-
ing of GluR6 kainate receptors when coexpressed in
HEK293 cells [9]. Here, we have used this assay to exam-
ine the enhanced ability of the cyclic peptide to disrupt
the GluR6/PSD-95 interaction. Compared to the linear
control peptide, the cyclic peptide is found to disrupt
the clustering of kainate receptors for extended periods
of time. The linear form of the peptide displays a maxi-
mum inhibitory function of 5 hr, which steadily drops off
and is completely abolished after 14 hr. In the same
assay, we observe that the cyclic peptide displays ap-
preciable inhibition of receptor clustering for 18 hr (Fig-
ure 6), consistent with enhanced enzymatic stability.
Significance
Figure 4. Specific Interactions of Cyclic Ligand with PDZ1
The shallow binding pocket of the canonical PDZ struc- Expanded view of the peptide/PDZ1 complex, illustrating many of
the residues involved in ligand binding (dark green).ture makes it an extremely challenging target for the
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Experimental Procedures
Synthesis
The peptide was one of a series of novel macrocyclic peptides
designed and prepared to function as conformationally constrained
ligands for the PDZ domain [7]. Based upon the C-terminal sequence
of CRIPT, this peptide possesses a bis-amide -Ala bridge that links
the P1 and P3 side chains. The peptide was synthesized using
standard Fmoc solid phase peptide synthetic protocols, modified
with orthogonal protecting groups for residues involved in the bridge
formation. The final product was purified by reverse-phase HPLC
and the mass confirmed by ESI-MS.
NMR Spectroscopy
All NMR spectra of the complex were collected at 25C on a Bruker
Avance 600 MHz spectrometer equipped with a triple resonance
probe and a triple axis gradient unit, while the spectra of the free
peptide were collected at 25C on a Bruker Avance 400 MHz
equipped with a triple axis gradient unit. TSP was used as direct
proton reference and as indirect 13C and 15N reference. The spectra
were processed with NMRPipe and analyzed with Sparky 3. Dis-
tance, dihedral angles, and scalar coupling restraints were obtained
from the NOESY spectra, from the chemical shift assignments, and
from HNHA spectra, respectively, following published procedures
[5]. Structures were calculated using the CNS program [10] em-
ploying the torsion angle simulated annealing protocol as described
previously [5], resulting in 23 structures with no NOE violation greater
Figure 5. Inhibition of PSD-95/GluR6 Interaction than 0.3 A˚, dihedral angle violation greater than 5, and coupling
constant violation greater than 1 Hz.Time profile of the action of the cyclic peptide in disrupting the
The conformation of the free peptide in solution was studied oninteraction between PSD-95-GluR6 subunit of the kainate receptor.
a 1 mM sample dissolved in 600 l of H2O (pH 4.5). The peptideA comparison of the cyclic peptide with the linear 15-amino acid
peptide containing the C terminus of GluR6 to compete against the resonances were assigned using DQF-COSY and TOCSY (mixing
PSD-95/GluR6 association as measured by immunoprecipitation. time 65 ms) experiments. The interproton distances were obtained
Even overnight (14 hr), the cyclic peptide remains active. from ROESY experiments employing a 280 ms mixing time and a
3.1 kHz spinlock field.
The NMR experiments of the PDZ1-peptide complex were per-
ring system extends over the 2-strand, interacting with formed on a 300 l solution containing 1 mM 15N/13C enriched pro-
tein, 3 mM peptide, 10 mM phosphate buffer, and 150 mM NaCl (pHa region of the PDZ domain with high sequence variabil-
6.8). The resonance assignment and measurement of intra- andity, providing a novel target for PDZ-domain specificity.
intermolecular NOEs were obtained by HNCA, CBCA(CO)NH, HBHAThe extended duration of bioactivity of the cyclic peptide
(CO)NH, HCCH-TOCSY, 15N-NOESY-HSQC, and 13C NOESY-HSQCis an important feature for the physiological character-
spectra following standard procedures [11, 12]. All of the backbone
ization of the role of the GluR6/PDZ1 association, as resonances were assigned, with the exception of the N- and
well as further development of this molecular scaffold C-terminal residues and the 15N resonances of the prolines. The
to target additional PDZ domains of PSD-95 as well as HNHA spectra were employed to evaluate the coupling constants
between the amide and the H protons [13].other PDZ containing proteins.
Figure 6. Kainate Receptor Clustering Inhi-
bition
Staining of the GluR6 subunit of the kainate
receptor in the presence of (A) the linear 15-
amino acid peptide containing the C terminus
of GluR6 and (B) the cyclic peptide. Both
peptides are active in the disruption of the
clustering of the kainate receptors, with the
cyclic peptide still active even after 14 hr
(overnight).
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Biological Function Assays ing of conformationally constrained cyclic ligands for the PDZ
domain. Bioorg. Med. Chem. Lett. 14, 1385–1388.Microscopy
The interaction of the GluR6 subunit of the kainate receptor with 8. Kozlov, G., Banville, D., Gehring, K., and Ekiel, I. (2002). Solution
structure of the PDZ2 domain from cytosolic human phospha-PSD-95 was examined by the amount of clustering detected by
microscopy. One 60 mm dish of HEK293 cells was transfected with tase hPTP1E complexed with a peptide reveals contribution of
the beta2-beta3 loop to PDZ domain-ligand interactions. J. Mol.GluR6GFP and PSD-95 cDNA constructs using Fugene 6 Transfec-
tion Reagent (Roche), then split onto poly-D-lysine coated cov- Biol. 320, 813–820.
9. Garcia, E.P., Mehta, S., Blair, L.A., Wells, D.G., Shang, J., Fuku-erslips. After 24–30 hr, the peptide was introduced via Bioporter
(Sigma). At the appropriate time points, the coverslips were fixed shima, T., Fallon, J.R., Garner, C.C., and Marshall, J. (1998).
SAP90 binds and clusters kainate receptors causing incompletewith paraformaldahyde, rinsed with 1 PBS, and mounted onto
slides for viewing. desensitization. Neuron 21, 727–739.
10. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros,Immunoblotting
In order to better quantify the effect of the peptide on the PSD-95/ P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges,
M., Pannu, N.S., et al. (1998). Crystallography & NMR system: AGluR6 interaction, a series of immunoprecipitations at differing time
points were conducted. HEK293 cells were transfected with PSD-95 new software suite for macromolecular structure determination.
Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.and myc-tagged GluR6 cDNA constructs. After 20–24 hr, the peptide
was added (3 g/ul of media) via the Bioporter reagent (Sigma) and 11. Clore, G.M., and Gronenborn, A.M. (1994). Young Investigator
Award Lecture. Structures of larger proteins, protein-ligand andincubated at 37C. After the appropriate time point, the dishes were
removed, carefully rinsed with DMEM and 1 TBS so as to not protein-DNA complexes by multidimensional heteronuclear
NMR. Protein Sci. 3, 372–390.disrupt the cells, then homogenized in a 1 SALTERS buffer (50 mM
Tris [pH 8.0], 150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 2 mM 12. Sattler, M., Schleucher, J., and Griesinger, C. (1999). Hetero-
nuclear multidimensional NMR experiments for the structureEDTA). The cells were then solubilized for 1 hr at 4C and cleared
by centrifugation at 14,000g for 30 min. The supernatant was ex- determination of proteins in solution employing pulsed field
gradients. Prog. NMR Spec. 34, 93–158.tracted and then incubated overnight with 4 g of c-myc primary
antibody (Santa Cruz). Protein G sepharose beads (Amersham Bio- 13. Vuister, G.W., and Bax, A. (1994). Measurement of four-bond
HN-H alpha J-couplings in staphylococcal nuclease. J. Biomol.sciences) were added to the extract and incubated at 4C for 1 hr.
After a series of washes with SALTERS, standard 2 protein loading NMR 4, 193–200.
buffer containing 4 mM DTT was added, the samples were boiled for
5 min, and resolved on an 8% SDS-PAGE. Gels were then Western
blotted, immunostained with -PSD-95 monoclonal antibody (Up-
state), and visualized with Supersignal West Pico chemiluminescent
substrate (Pierce). The blots were analyzed using ImageJ (NIH) to
calculate densitometry units and graphed with SigmaPlot (SPSS).
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